RASopathies and hemostatic abnormalities: key role of platelet dysfunction.
Abnormal platelet function
Bleeding disorders
Laboratory test abnormalities
Noonan syndrome
Platelet optical aggregometry
RASopathies
Screening surgical procedures
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
02 12 2021
02 12 2021
Historique:
received:
19
04
2021
accepted:
06
11
2021
entrez:
3
12
2021
pubmed:
4
12
2021
medline:
12
3
2022
Statut:
epublish
Résumé
Bleeding anomalies have been reported in patients affected by Noonan syndrome. No study has been performed in patients with molecularly confirmed RASopathy. We aimed to characterize the frequency and types of bleeding disorders in patients with RASopathies and evaluate any significant association with laboratory findings. Forty-nine individuals (PTPN11, n = 27; SOS1, n = 7; RIT1, n = 3; SPRED1, n = 1; LZTR1, N = 3; RAF1, n = 2; BRAF, n = 4; MEK1, n = 1; MEK2, n = 1), and 49 age- and sex-matched controls were enrolled. The "Paediatric Bleeding Questionnaire Scoring Key" was administered to patients and families. Laboratory screening tests including clotting factors dosing, platelet count, Prothrombin Time and Partial Thromboplastin Time, were employed both in patients and controls to characterize the bleeding diathesis. A subgroup of 29/49 patients and 29/49 controls was also tested for platelet function. Regardless of the gene involved, pathological paediatric bleeding scores were recorded in 14/49 (28.5%) patients. Indeed, 7 were mutated in PTPN11, 3 in SOS1, 2 in RIT1, 1 in BRAF, and 1 in MEK1. Compared to patients with normal bleeding scores, those with pathologic bleeding score showed higher prevalence of splenomegaly (p = 0.006), prolonged aPTT (p = 0.04), lower levels of coagulation factor V (FV, p = 0.001), FVII (p = 0.003), FX (p = 0.0008) and FXIII (p = 0.002), higher vWAg (p = 0.04), and lower platelet sensitivity to Ristocetin (p = 0.001), arachidonic acid (AA) (p = 0.009) and collagen (p = 0.01). The presence of hematomas inversely correlated with factor V (p = 0.002), factor VII (p = 0.003), factor X (p = 0.002) and factor XIII (p = 0.004) levels, and directly correlated with platelet response to collagen (p = 0.02) and AA (p = 0.01). The presence of splenomegaly directly correlated with the presence of hematoma (p = 0.006), platelet response to Ristocetin (p = 0.04) and AA (p = 0.04), and inversely correlated with factor V levels (p = 0.03). Patients with RASopathies and a bleeding tendency exhibit multiple laboratory abnormalities, including platelet-related disorders. Splenomegaly is frequently detected and might be a suggestive sign for qualitative platelet dysfunction. A comprehensive clinical assessment should be carried out at diagnosis, during the follow-up and before any surgical procedures. Since there is currently no consensus on management of bleeding complications, it is important that physicians closely monitor these patients.
Sections du résumé
BACKGROUND
Bleeding anomalies have been reported in patients affected by Noonan syndrome. No study has been performed in patients with molecularly confirmed RASopathy. We aimed to characterize the frequency and types of bleeding disorders in patients with RASopathies and evaluate any significant association with laboratory findings.
PATIENTS AND METHODS
Forty-nine individuals (PTPN11, n = 27; SOS1, n = 7; RIT1, n = 3; SPRED1, n = 1; LZTR1, N = 3; RAF1, n = 2; BRAF, n = 4; MEK1, n = 1; MEK2, n = 1), and 49 age- and sex-matched controls were enrolled. The "Paediatric Bleeding Questionnaire Scoring Key" was administered to patients and families. Laboratory screening tests including clotting factors dosing, platelet count, Prothrombin Time and Partial Thromboplastin Time, were employed both in patients and controls to characterize the bleeding diathesis. A subgroup of 29/49 patients and 29/49 controls was also tested for platelet function.
RESULTS
Regardless of the gene involved, pathological paediatric bleeding scores were recorded in 14/49 (28.5%) patients. Indeed, 7 were mutated in PTPN11, 3 in SOS1, 2 in RIT1, 1 in BRAF, and 1 in MEK1. Compared to patients with normal bleeding scores, those with pathologic bleeding score showed higher prevalence of splenomegaly (p = 0.006), prolonged aPTT (p = 0.04), lower levels of coagulation factor V (FV, p = 0.001), FVII (p = 0.003), FX (p = 0.0008) and FXIII (p = 0.002), higher vWAg (p = 0.04), and lower platelet sensitivity to Ristocetin (p = 0.001), arachidonic acid (AA) (p = 0.009) and collagen (p = 0.01). The presence of hematomas inversely correlated with factor V (p = 0.002), factor VII (p = 0.003), factor X (p = 0.002) and factor XIII (p = 0.004) levels, and directly correlated with platelet response to collagen (p = 0.02) and AA (p = 0.01). The presence of splenomegaly directly correlated with the presence of hematoma (p = 0.006), platelet response to Ristocetin (p = 0.04) and AA (p = 0.04), and inversely correlated with factor V levels (p = 0.03).
CONCLUSIONS
Patients with RASopathies and a bleeding tendency exhibit multiple laboratory abnormalities, including platelet-related disorders. Splenomegaly is frequently detected and might be a suggestive sign for qualitative platelet dysfunction. A comprehensive clinical assessment should be carried out at diagnosis, during the follow-up and before any surgical procedures. Since there is currently no consensus on management of bleeding complications, it is important that physicians closely monitor these patients.
Identifiants
pubmed: 34857025
doi: 10.1186/s13023-021-02122-7
pii: 10.1186/s13023-021-02122-7
pmc: PMC8638204
doi:
Substances chimiques
Hemostatics
0
LZTR1 protein, human
0
Transcription Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
499Informations de copyright
© 2021. The Author(s).
Références
J Pediatr. 2004 Mar;144(3):368-74
pubmed: 15001945
Best Pract Res Clin Endocrinol Metab. 2011 Feb;25(1):161-79
pubmed: 21396583
J Hum Genet. 2016 Jan;61(1):33-9
pubmed: 26446362
Arch Dis Child. 1992 Feb;67(2):178-83
pubmed: 1543375
J Med Genet. 2004 Nov;41(11):e117
pubmed: 15520399
Am J Med Genet. 1988 Feb;29(2):277-82
pubmed: 3354599
Am J Hum Genet. 2020 Sep 3;107(3):499-513
pubmed: 32721402
Lancet. 1992 Jan 4;339(8784):19-21
pubmed: 1345952
Endocr Rev. 2018 Oct 1;39(5):676-700
pubmed: 29924299
Thromb Res. 2012 Nov;130(5):e251-4
pubmed: 22985731
Mol Syndromol. 2010 Feb;1(1):2-26
pubmed: 20648242
Eur J Med Genet. 2015 Oct;58(10):509-25
pubmed: 26341048
Blood. 2013 May 16;121(20):4205-20
pubmed: 23509158
Blood. 2019 Dec 19;134(25):2304-2317
pubmed: 31562133
J Gastroenterol Hepatol. 2004 Oct;19(10):1217-9
pubmed: 15377306
Pediatr Blood Cancer. 2012 Feb;58(2):167-72
pubmed: 22012616
Am J Hum Genet. 2006 Feb;78(2):279-90
pubmed: 16358218
Nat Genet. 2001 Dec;29(4):465-8
pubmed: 11704759
J Blood Med. 2018 Oct 23;9:185-192
pubmed: 30464668
J Pediatr. 1983 Feb;102(2):224-7
pubmed: 6822926
J Pediatr. 2020 May;220:154-158.e6
pubmed: 32111381
Haemophilia. 2014 Nov;20(6):831-5
pubmed: 25196510
Pediatrics. 2014 May;133(5):e1299-304
pubmed: 24753526
Rev Hosp Clin Fac Med Sao Paulo. 2003 Jan-Feb;58(1):5-8
pubmed: 12754583
Lancet. 2013 Jan 26;381(9863):333-42
pubmed: 23312968
Acta Paediatr. 1996 Oct;85(10):1181-5
pubmed: 8922080
J Thromb Haemost. 2013 Oct;11(10):1800-13
pubmed: 24015866
J Biol Chem. 2006 Mar 10;281(10):6785-92
pubmed: 16377799
J Pediatr Hematol Oncol. 2010 Oct;32(7):532-6
pubmed: 20686427